Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vincristine Sulfate

FDA-approved product (injectable, injection), marketed as Marqibo Kit, Oncovin, Vincasar Pfs and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vincristine Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vincristine Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vincristine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

    NCT00022178 · start 1998-12

    Registered record
    Registry ID
    NCT00022178
    Conditions
    Carcinoma of Unknown Primary
    Interventions
    cisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; fluorouracil; vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    1998-12
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma of Unknown Primary
    Interventioncisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride +2 more
    PhasePhase 3
    Registry statusUnknown

  • Combination Chemotherapy in Treating Children With Progressive Brain Tumors

    NCT00002944 · start 1997-04

    Registered record
    Registry ID
    NCT00002944
    Conditions
    Brain Tumors; Central Nervous System Tumors
    Interventions
    carboplatin; lomustine; procarbazine hydrochloride; thioguanine; vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-04
    Completion
    2012-04
    Enrolment
    428

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Tumors; Central Nervous System Tumors
    Interventioncarboplatin; lomustine; procarbazine hydrochloride; thioguanine +1 more
    PhasePhase 3
    Registry statusCompleted

  • Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

    NCT00002827 · start 1996-10

    Registered record
    Registry ID
    NCT00002827
    Conditions
    Cardiac Toxicity; Lymphoma
    Interventions
    bleomycin sulfate; filgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET electron therapy; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-10
    Completion
    2008-06
    Enrolment
    294

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Lymphoma
    Interventionbleomycin sulfate; filgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride +5 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy in Treating Children With Lymphoma

    NCT00002590 · start 1994-07

    Registered record
    Registry ID
    NCT00002590
    Conditions
    Lymphoma
    Interventions
    filgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; pegaspargase; prednisone; thioguanine; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1994-07
    Completion
    2007-03
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride +9 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

    NCT00002494 · start 1992-05

    Registered record
    Registry ID
    NCT00002494
    Conditions
    Leukemia; Lymphoma
    Interventions
    cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; leucovorin calcium; mesna; methotrexate; prednisone; therapeutic hydrocortisone; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1992-05
    Completion
    2006-01
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventioncyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride +10 more
    PhasePhase 2
    Registry statusCompleted